Navigation Links
Cellceutix Discovers Drug Activates 'Guardian Angel p53' in Fight Against Leukemia
Date:3/7/2011

reated with Kevetrin took a median of 32 days to reach 1000 mm3 in volume whereas control mice took only 15 days, resulting in a Tumor Growth Delay of 110%.  In addition, after Kevetrin treatment, the tumors in 14% of the mice completely regressed for a period of 3 weeks. This was achieved with no significant weight loss in the animals. This represents more potent anti-tumor activity compared to historical data with standard leukemia chemotherapies, Vincristine or Daunorubicin, in a human xenograft model, e.g., Vincristine (0.2 mg/kg every other day for 1 week) reduced tumor volumes by 55% and Daunorubicn (1 mg/kg every other day for 2 weeks) reduced tumor volume by 30% in the MOLM-13 acute myeloid leukemia xenograft model (Yang 2007 Blood 110:2034).

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, "Kevetrin continues to exceed our original expectations as a possible new cancer therapy. Dr. Frei is amongst the most elite cancer researchers in the history of the disease.  For Kevetrin to impress him is really saying something about the possibilities of this novel compound."

Cellceutix has been notified by its  formulation vendor that production is scheduled to begin this week to produce Kevetrin in the dosage form for planned clinical trials. The Company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in May 2011, with human trials to begin thereafter.

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Rele
'/>"/>

SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
2. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
9. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
10. deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
11. deCODE Discovers Four New Risk Factors for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... (HealthDay News) -- Celebration can quickly turn to ... Day, experts say. Over the last decade, more ... while people were using turkey fryers, according to the ... cared for a patient who tried to deep fry ... in any circumstances," Dr. Arthur Sanford, a burn surgeon ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin ... parabens and other cancer-causing agents, but they are also ... awareness programs that help in the fight against breast ... an incredible, record-breaking contribution of $30,000 through participation in ... Sweet Red Rose Whip Moisturizer and the company’s corporate ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
(Date:11/28/2014)... A newly released article from Community Health ... virus that will soon be spreading across the United States ... with a brief explanation of what the influenza virus is ... children under the age of 5, adults over the age ... heart and lung diseases, asthma, or diabetes, are at higher ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... Additional leadership needed to manage growthWAYNE, Pa. March 10 ... software, workflow tools and consulting services, is adding two ... line in order to best manage its growing client ... Vice President of Audit and Education Services and James ...
... 10 More physician leaders are embracing technological advances, ... them clunky and unresponsive to their needs.Those are the ... College of Physician Executives (ACPE). The findings were published ... ACPE,s journal of medical management.ACPE conducted the same survey ...
... LCAV ) today announced that following a rigorous clinical comparison ... to reduce the number of platforms at each of its ... The Company expects this will reduce annual operating expenses in ... no later than the end of the third quarter of ...
... 10, 2009 Forest Laboratories, Inc. (NYSE: FRX ... KGaA, and Merz Pharmaceuticals GmbH announced today that the U.S. ... Determination granting the full five years of patent term extension ... listed in the U.S. Food and Drug Administration Orange Book ...
... Safety Week, the spotlight shifts to the 30,000 dental assistants ... who help ensure that sedation dentistry is as safe for ... much an all-team responsibility," says Dr. Michael Silverman, national chairman ... sedation dentistry educators. , ...
... signs multi-year agreement with PureWellness to provide comprehensive employee wellness program ... ... 2009 -- PureWellness, Inc, a leading provider of online wellness solutions, ... in Plano, TX, to provide a comprehensive online wellness program for ...
Cached Medicine News:Health News:Precyse Solutions Adds Executives, Realigns Around Service Lines 2Health News:Survey Results: Health Care Technology Advances as Physician Frustration Grows 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 3Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 4Health News:USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R) 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 3Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 2Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: